MULTIPLE

GOG -0136: ACQUISITION OF HUMAN GYNECOLOGIC SPECIMENS AND SERUM TO BE USED IN STUDYING THE CAUSES, DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER

OVARIAN

GOG -0187: PHASE II STUDY OF PACLITAXEL FOR OVARIAN STROMAL TUMORS AS SECOND-LINE THERAPY

GOG-0212: A RANDOMIZED PHASE III TRIAL OF MAINTENANCE CHEMOTHERAPY COMPARING 12 MONTHLY CYCLES OF SINGLE AGENT PACLITAXEL OR CT-2103 (IND# 70177) VERSUS NO TREATMENT UNTIL DOCUMENTED RELAPSE IN WOMEN WITH ADVANCED OVARIAN OR PRIMARY PERITONEAL CANCER WHO ACHIEVE A COMPLETE CLINICAL RESPONSE TO PRIMARY PLATINUM/TAXANE CHEMOTHERAPY

GOG-0241: A GCIG INTERGROUP MULTICENTER PHASE III TRIAL OF OPEN LABEL CARBOPLATIN AND PACLITAXEL +/- NCI SUPPLIED AGENT: BEVACIZUMAB COMPARED WITH OXALIPLATIN AND CAPECITABINE +/- BEVACIZUMAB AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH MUCINOUS EPITHELIAL OVARIAN OR FALLOPIAN TUBE CANCER

GOG-0252: A PHASE III CLINICAL TRIAL OF BEVACIZUMAB WITH IV VERSUS IP CHEMOTHERAPY IN OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CARCINOMA

GOG-0260: A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

GOG-0262: A RANDOMIZED PHASE III TRIAL OF EVERY -3-WEEKS PACLITAXEL VERSUS DOSE DENSE WEEKLY PACLITAXEL IN COMBINATION WITH CARBOPLATIN WITH OR WITHOUT CONCURRENT AND CONSOLIDATION BEVACIZUMAB IN THE TREATMENT OF PRIMARY STAGE III OR IV EPITHELIAL OVARIAN, PERITONEAL OR FALLOPIAN TUBE CANCER

GOG-0264: A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VS. BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED ADVANCED STAGE AND RECURRENT CHEMONAIVE STAGE SEX CORD-STROMAL TUMORS OF THE OVARY
GOG-9925: A PHASE I STUDY OF VTX-2337 (IND #78,416) IN COMBINATION WITH DOXIL (NSC# 712227) IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

OVA2: MARKER DISCOVERY AND CLINICAL TRIAL TESTING FOR OVA2 USING SERUM FROM WOMEN WITH A DOCUMENTED OVARIAN ADNEXAL MASS

OVB-2003: BIOMARKER DISCOVERY IN OVARIAN TUMORS AND OTHER GYNECOLOGIC CONDITIONS

ENDOMETRIAL

GOG-0086P: A THREE ARM RANDOMIZED PHASE II STUDY OF PACLITAXEL/CARBOPLATIN/BEVACIZUMAB, PACLITAXEL/CARBOPLATIN/TEMSIROLIMUS AND IXABEPILONE/CARBOPLATIN/BEVACIZUMAB AS INITIAL THERAPY FOR MEASURABLE STAGE III OR IVA, STAGE IVB, OR RECURRENT ENDOMETRIAL CANCER

GOG-0238: A RANDOMIZED TRIAL OF PELVIC IRRADIATION WITH OR WITHOUT CONCURRENT WEEKLY CISPLATIN IN PATIENTS WITH PELVIC-ONLY RECURRENCE OF CARCINOMA OF THE UTERINE CORPUS

GOG-0249: PHASE III TRIAL OF PELVIC RADIATION THERAPY VERSUS VAGINAL CUFF BRACHYTHERAPY FOLLOWED BY PACLITAXEL/CARBOPLATIN IN PATIENTS WITH HIGH-RISK, EARLY STAGE ENDOMETRIAL CANCER

GOG-0258: A RANDOMIZED PHASE III TRIAL OF CISPLATIN AND TUMOR VOLUME DIRECTED IRRADIATION FOLLOWED BY CARBOPLATIN AND PACLITAXEL VS. CARBOPLATIN AND PACLITAXEL FOR OPTIMALLY DEBULKED, ADVANCED ENDOMETRIAL CARCINOMA

GOG-0261: A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN VERSUS IFOSFAMIDE PLUS PACLITAXEL IN CHEMOTHERAPY-NAÏVE PATIENTS WITH NEWLY DIAGNOSED STAGE I-IV, PERSISTENT OR RECURRENT CARCINOSARCOMA (MIXED MESODERMAL TUMORS) OF THE UTERUS OR OVARY
CERVIX

GOG-0240: A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BEVACIZUMAB VERSUS THE NONPLATINUM DOUBLET, TOPOTECAN PLUS PACLITAXEL, WITH AND WITHOUT NCI-SUPPLIED BEVACIZUMAB, IN STAGE IVB, RECURRENT OR PERSISTENT CARCINOMA OF THE CERVIX

GOG-0263: RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY

Studies Under Construction

11-GYN-130: Treatment of Endometrial Cancer Utilizing Pathology Intraoperative Consultation to Determine Extent of Surgical Staging (Ueland)

11-GYN-098: Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol(Miller)